C4 Therapeutics (CCCC) Competitors $2.12 +0.07 (+3.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.16 +0.04 (+1.89%) As of 08/1/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CCCC vs. DNTH, DAWN, ATAI, AUTL, XNCR, ABVX, TLRY, MRVI, PRME, and RLAYShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Dianthus Therapeutics (DNTH), Day One Biopharmaceuticals (DAWN), atai Life Sciences (ATAI), Autolus Therapeutics (AUTL), Xencor (XNCR), Abivax (ABVX), Tilray Brands (TLRY), Maravai LifeSciences (MRVI), Prime Medicine (PRME), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Its Competitors Dianthus Therapeutics Day One Biopharmaceuticals atai Life Sciences Autolus Therapeutics Xencor Abivax Tilray Brands Maravai LifeSciences Prime Medicine Relay Therapeutics Dianthus Therapeutics (NASDAQ:DNTH) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation. Do analysts prefer DNTH or CCCC? Dianthus Therapeutics presently has a consensus price target of $53.00, suggesting a potential upside of 157.41%. C4 Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 466.04%. Given C4 Therapeutics' higher probable upside, analysts plainly believe C4 Therapeutics is more favorable than Dianthus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to DNTH or CCCC? In the previous week, Dianthus Therapeutics and Dianthus Therapeutics both had 1 articles in the media. Dianthus Therapeutics' average media sentiment score of 0.00 equaled C4 Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, DNTH or CCCC? Dianthus Therapeutics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.97, suggesting that its stock price is 197% more volatile than the S&P 500. Do institutionals & insiders hold more shares of DNTH or CCCC? 47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 8.2% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 8.7% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is DNTH or CCCC more profitable? C4 Therapeutics has a net margin of -259.60% compared to Dianthus Therapeutics' net margin of -1,544.23%. Dianthus Therapeutics' return on equity of -29.26% beat C4 Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-1,544.23% -29.26% -27.87% C4 Therapeutics -259.60%-45.86%-28.96% Which has stronger earnings and valuation, DNTH or CCCC? Dianthus Therapeutics has higher earnings, but lower revenue than C4 Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$6.24M106.12-$84.97M-$2.88-7.15C4 Therapeutics$35.58M4.23-$105.32M-$1.47-1.44 SummaryC4 Therapeutics beats Dianthus Therapeutics on 8 of the 14 factors compared between the two stocks. Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$145.57M$3.00B$5.48B$9.52BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-1.4417.6228.6723.80Price / Sales4.23178.97373.5466.64Price / CashN/A41.9535.4557.96Price / Book0.698.508.275.55Net Income-$105.32M-$55.06M$3.24B$259.03M7 Day Performance-6.19%-3.98%-3.69%-4.59%1 Month Performance39.47%9.59%4.33%4.46%1 Year Performance-66.98%6.72%25.95%18.03% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics2.3838 of 5 stars$2.12+3.4%$12.00+466.0%-68.3%$145.57M$35.58M-1.44150News CoverageUpcoming EarningsDNTHDianthus Therapeutics1.2237 of 5 stars$20.74+1.7%$53.00+155.5%-26.5%$656.06M$6.24M0.0080Upcoming EarningsDAWNDay One Biopharmaceuticals2.2503 of 5 stars$6.40flat$29.00+353.1%-53.1%$648.72M$131.16M-9.0160Upcoming EarningsATAIatai Life Sciences2.9699 of 5 stars$3.53+9.3%$9.00+155.0%+193.7%$647.09M$310K-3.8880Analyst ForecastShort Interest ↑Analyst RevisionGap DownHigh Trading VolumeAUTLAutolus Therapeutics2.3438 of 5 stars$2.43+0.8%$9.32+283.5%-47.9%$641.40M$10.12M-2.76330Gap DownXNCRXencor3.4779 of 5 stars$9.10+1.4%$28.00+207.7%-59.9%$638.40M$110.49M-2.97280News CoverageUpcoming EarningsShort Interest ↑ABVXAbivax3.6107 of 5 stars$10.14+1.9%$31.00+205.7%+511.7%$631.55MN/A0.0061News CoverageAnalyst ForecastGap DownHigh Trading VolumeTLRYTilray Brands2.8903 of 5 stars$0.67+8.4%$1.92+184.6%-71.4%$625.34M$788.94M-0.642,650Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionGap DownMRVIMaravai LifeSciences3.7585 of 5 stars$2.38-2.1%$6.64+178.9%-76.9%$618.82M$259.18M-2.09610Gap DownPRMEPrime Medicine3.7426 of 5 stars$4.57+10.7%$9.25+102.4%-22.2%$614.65M$3.85M-2.23234News CoverageInsider TradeGap DownHigh Trading VolumeRLAYRelay Therapeutics1.9652 of 5 stars$3.63+3.7%$17.67+386.7%-57.9%$600.06M$10.01M-1.63330News CoverageUpcoming Earnings Related Companies and Tools Related Companies Dianthus Therapeutics Competitors Day One Biopharmaceuticals Competitors atai Life Sciences Competitors Autolus Therapeutics Competitors Xencor Competitors Abivax Competitors Tilray Brands Competitors Maravai LifeSciences Competitors Prime Medicine Competitors Relay Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CCCC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
